Vertex Pharmaceuticals Inc / Ma
VRTXNasdaqCIK 875320HealthcareFiscal year ends Dec 31
Reports and events: 287 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2020:09 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000875320-26-000278 |
| 2026-09-0120:25 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000875320-26-000264 |
| 2026-08-0420:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0000875320-26-000259 |
| 2026-08-0320:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-26-000256 |
| 2026-07-0701:55 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-296710 |
| 2026-05-1320:03 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000875320-26-000204 |
| 2026-05-0520:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0000875320-26-000173 |
| 2026-05-0420:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-26-000171 |
| 2026-04-2920:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000875320-26-000166 |
| 2026-04-0220:02 ET | DEF 14A | Proxy statementPeriod 2026-05-13 | 0000875320-26-000153 |
| 2026-03-3120:03 ET | 8-K | 8.01 Other events | 0000875320-26-000147 |
| 2026-02-1321:20 ET | 10-K | Annual reportPeriod 2025-12-31 | 0000875320-26-000056 |
| 2026-02-1221:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-26-000034 |
| 2025-11-0421:03 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0000875320-25-000232 |
| 2025-11-0321:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-25-000230 |
| 2025-08-0520:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000875320-25-000216 |
| 2025-08-0420:06 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000875320-25-000213 |
| 2025-05-1920:24 ET | 8-K | 8.01 Other events | 0000875320-25-000199 |
| 2025-05-1420:08 ET | 8-K | 5.07 Shareholder vote results | 0000875320-25-000194 |
| 2025-05-0620:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000875320-25-000192 |
| 2025-05-0520:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-25-000171 |
| 2025-04-0320:02 ET | DEF 14A | Proxy statementPeriod 2025-05-14 | 0000875320-25-000160 |
| 2025-03-2820:08 ET | 8-K | 8.01 Other events | 0000875320-25-000156 |
| 2025-02-1321:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000875320-25-000053 |
| 2025-02-1021:08 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000875320-25-000029 |
| 2024-12-2020:51 ET | 8-K | 7.01 Regulation FD disclosure | 0000875320-24-000231 |
| 2024-11-0521:11 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000875320-24-000223 |
| 2024-11-0421:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-24-000221 |
| 2024-08-1620:04 ET | 8-K | 1.01 Entry into a material agreement | 0000875320-24-000207 |
| 2024-08-0220:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000875320-24-000198 |
| 2024-08-0120:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-24-000193 |
| 2024-06-2720:05 ET | 8-K | 8.01 Other events | 0000875320-24-000178 |
| 2024-05-2012:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-142278 |
| 2024-05-1520:12 ET | 8-K | 5.07 Shareholder vote results | 0000875320-24-000142 |
| 2024-05-0720:14 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000875320-24-000139 |
| 2024-05-0620:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-24-000137 |
| 2024-04-1111:13 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-092475 |
| 2024-04-0420:01 ET | DEF 14A | Proxy statementPeriod 2023-05-15 | 0001308179-24-000452 |
| 2024-02-1521:12 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000875320-24-000062 |
| 2024-02-0521:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-24-000012 |
| 2023-12-0817:59 ET | 8-K | 8.01 Other events | 0000875320-23-000054 |
| 2023-12-0521:14 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000875320-23-000047 |
| 2023-11-0721:16 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000875320-23-000031 |
| 2023-11-0621:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-23-000029 |
| 2023-10-0520:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000875320-23-000023 |
| 2023-08-0220:05 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000875320-23-000021 |
| 2023-08-0120:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-23-000019 |
| 2023-06-0516:10 ET | SC 13D/A | Ownership report, active investor, amended | 0001341004-23-000148 |
| 2023-05-1812:56 ET | 8-K | 5.07 Shareholder vote results | 0000875320-23-000015 |
| 2023-05-0220:07 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000875320-23-000012 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.